Novel therapeutics in multiple myeloma. - Wikidata - wikimedia - TriplyDB

Novel therapeutics in multiple myeloma.

Novel therapeutics in multiple myeloma.

http://www.wikidata.org/entity/Q34637538

about

Endoplasmic reticulum stress plays a pivotal role in cell death mediated by the pan-deacetylase inhibitor panobinostat in human hepatocellular cancer cells.Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells.

P2860

Q30455973-0AA750FA-3A1A-43D2-BFBA-83F49530B73F Q33886073-DE3200E3-490F-43B3-A721-16061C8457A7 Q34500544-DE2DCDCB-502C-4084-9EBE-85A7154270BB Q36691554-BAED5867-8E0D-481C-9CCB-95E11D1633D3 Q38193997-DA2A5931-6E75-42F8-B5BF-709ED2A27059 Q39174431-F3E805C1-2E01-4422-AAFF-2B0EA7EF9813 Q39234159-790BB56E-314E-4246-AEC7-C59FF11E926F Q42563273-E0B06630-2549-416D-854B-B2F83B68F476

P2860

Novel therapeutics in multiple myeloma.

http://www.wikidata.org/entity/Q34637538

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Novel therapeutics in multiple myeloma.

@ast

Novel therapeutics in multiple myeloma.

@en

Novel therapeutics in multiple myeloma.

@nl

type

label

Novel therapeutics in multiple myeloma.

@ast

Novel therapeutics in multiple myeloma.

@en

Novel therapeutics in multiple myeloma.

@nl

prefLabel

Novel therapeutics in multiple myeloma.

@ast

Novel therapeutics in multiple myeloma.

@en

Novel therapeutics in multiple myeloma.

@nl

P1433

Q34637538-18FE771F-7D11-4F45-A2BD-17F07CFCB92E

P1476

Q34637538-DF4F3356-C004-46B1-B821-D80B9A97AEF2

P2093

Q34637538-832603FA-4309-46A9-83B3-D5B62DF465CC

P2860

Q34637538-2B37D0BA-9564-4003-9338-B078EE15D8C3

Q34637538-32B0BCEE-EA76-40A8-812D-E6CEC05C1341

Q34637538-3602298E-EDFD-425D-88EE-0535AC7887B9

Q34637538-3D3D1AA7-8AE1-46F2-8A4C-C774702C1CBC

Q34637538-6D6B4EFD-5C02-484B-BBEB-D7595BF3E4E7

Q34637538-87AABD49-E5B9-46DE-8231-B123DEE08646

Q34637538-8CC0C1BF-8703-481F-8B4C-F3646EE9E5BA

Q34637538-999266BD-1020-40A7-8401-B1034301C345

Q34637538-AF9666C3-552B-4E29-81C0-9EDA3312C5DD

Q34637538-BEC48976-DEE7-4CED-852C-541DCDFAAF39

P304

Q34637538-A83B8103-2D0F-4E70-955C-BA392351AF28

P31

Q34637538-ABB75CE1-CDA1-4F8D-B981-9895427A8419

P356

Q34637538-C607C993-0301-45CB-B340-FFD9B9D7ABF1

P478

Q34637538-6D5CD89F-9166-4DC2-80B7-4E564FB7EE7D

P577

Q34637538-D0729DE1-32D4-4FE2-ACDA-7B2AB0923D35

P698

Q34637538-7EB19598-E06C-42B0-AF83-557A0D953AC9

P921

Q34637538-AF134E16-E9B6-48A5-9B80-06EBE59BC5DF

Q34637538-F0FD6C1E-87B5-4C30-A981-50E6165C01F7

P932

Q34637538-9714AC68-A7F3-403D-814C-99828980E8D8

P356

102453312X13336169156131

P1433

P1476

Novel therapeutics in multiple myeloma.

@en

P2093

A Keith Stewart

http://www.w3.org/2001/XMLSchema#string

P2860

Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

Carfilzomib: a novel second-generation proteasome inhibitor

Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.

Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.

A novel proteasome inhibitor NPI-0052 as an anticancer therapy.

P304

S105-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1179/102453312X13336169156131

http://www.w3.org/2001/XMLSchema#string

P478

17 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22507794

http://www.w3.org/2001/XMLSchema#string

P921

P932

3905954

http://www.w3.org/2001/XMLSchema#string